Li et al. found that AT1R blocker and partial PPAR-γ agonist (telmisartan) promoted the mRNA expression of adiponectin, an anti-inflammatory adipokine, and decreased the mRNA levels of the inflammatory markers’ leptin, IL-6 and IL-17, in inflamed mesenteric adipose tissue from patients with Crohn’s disease [52]. Here, IL6 is linked to Crohn disease.